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Abstract
Background: Glutathione, the main antioxidant of intestinal epithelial cells, is suggested to play an
important role in gut barrier function and prevention of inflammation-related oxidative damage as
induced by acute bacterial infection. Most studies on intestinal glutathione focus on oxidative stress
reduction without considering functional disease outcome. Our aim was to determine whether
depletion or maintenance of intestinal glutathione changes susceptibility of rats to Salmonella
infection and associated inflammation.
Rats were fed a control diet or the same diet supplemented with buthionine sulfoximine (BSO;
glutathione depletion) or cystine (glutathione maintenance). Inert chromium ethylenediamine-
tetraacetic acid (CrEDTA) was added to the diets to quantify intestinal permeability. At day 4 after
oral gavage with Salmonella enteritidis (or saline for non-infected controls), Salmonella translocation
was determined by culturing extra-intestinal organs. Liver and ileal mucosa were collected for
analyses of glutathione, inflammation markers and oxidative damage. Faeces was collected to
quantify diarrhoea.
Results:  Glutathione depletion aggravated ileal inflammation after infection as indicated by
increased levels of mucosal myeloperoxidase and interleukin-1β. Remarkably, intestinal
permeability and Salmonella  translocation were not increased. Cystine supplementation maintained
glutathione in the intestinal mucosa but inflammation and oxidative damage were not diminished.
Nevertheless, cystine reduced intestinal permeability and Salmonella translocation.
Conclusion:  Despite increased infection-induced mucosal inflammation upon glutathione
depletion, this tripeptide does not play a role in intestinal permeability, bacterial translocation and
diarrhoea. On the other hand, cystine enhances gut barrier function by a mechanism unlikely to be
related to glutathione.
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Background
During foodborne Salmonella enteritidis infection patho-
gens can pass the gut epithelial cell lining and translocate
to extra-intestinal organs like the spleen and liver[1]. In
response to mucosal invasion of pathogens, epithelial
cells and macrophages express pro-inflammatory
cytokines, e.g. interleukin-1β (IL-1β), to recruit neu-
trophils[2,3]. These efficient killers of translocating
microbes [4] contain high concentrations of the enzyme
myeloperoxidase (MPO)[4,5], which participates in the
innate immune defence through formation of powerful
reactive oxidants[4,5]. An unfortunate side-effect of this
defence machinery is that the anti-bacterial reactive oxy-
gen species produced also react with cellular organic mol-
ecules and have the potential to induce oxidative tissue
damage [4-6]. For example, MPO is associated with oxida-
tive stress-related damage (protein nitration) in the
inflamed mucosa of ulcerative colitis patients[7]. To
reduce this damage, inhibition of MPO has even become
a possible target of new drug development[8].
Glutathione, a tripeptide composed of γ-glutamic acid,
cysteine and glycine is quantitatively the most important
low-molecular-weight (non-protein) thiol in tis-
sues[6,9,10]. Glutathione, synthesised by most mamma-
lian cells but mainly in the liver[9,11], is an active free-
radical-scavenging compound found in virtually all ani-
mal cells[6,9,11]. In comparison with a number of other
tissues the liver has a particularly high content of glutath-
ione[9]. A relatively high concentration of glutathione is
also detected in the intestinal epithelium[12]. Here glu-
tathione has been shown to play an important role in the
protection of the intestinal mucosa against oxidative stress
both in vitro [13,14] and in vivo[12,15]. For example, glu-
tathione depletion in newborn rats leads to increased nit-
rosative stress during necrotising enterocolitis[15].
Furthermore,  Salmonella infection decreases enterocyte
glutathione levels in mouse ileal loops and this reduction
increases the susceptibility of epithelial cells to oxidative
damage[16]. This oxidative damage in its turn might
impair barrier function. As well as the gut microbiota[17],
mucus[18] and the immune system[19,20], intestinal glu-
tathione is suggested to be important for intestinal barrier
function[15]. Many studies on the role of glutathione in
prevention of oxidative damage in the intestinal mucosa
have been performed [13-15]. However, actual in vivo
proof that intestinal glutathione is important for gut bar-
rier function is lacking. We therefore investigated the role
of glutathione in intestinal barrier function and infection-
induced mucosal inflammation.
Buthionine sulfoximine (BSO) is a specific inhibitor of γ-
glutamylcysteine synthetase (gamma-GCS), which is the
rate-limiting enzyme of glutathione synthesis[21]. This
chemical causes glutathione-deficiency in animals[22]
and enables us to investigate the role of this tripeptide in
animal models. Besides glutathione depletion, stimula-
tion of synthesis is interesting for that purpose as well.
Cysteine is known to stimulate glutathione synthesis[23],
and cysteine availability is often the limiting factor for
intracellular glutathione synthesis[24]. For example,
intraperitoneally administered N-acetylcysteine was
shown to increase hepatic and intestinal glutathione lev-
els in bile-duct ligated rats[25]. Therefore, dietary supple-
mentation with cysteine, or the more stable variant
cystine, can potentially maintain or increase hepatic and
intestinal glutathione levels during oxidative stress.
Our aim was to determine whether depletion of glutath-
ione by BSO affects gut barrier function and increases sus-
ceptibility of rats to Salmonella infection and the
associated inflammation. In addition, the effect of dietary
cystine on glutathione levels in the intestinal mucosa and
consequences for the resistance to infection were investi-
gated.
Results
Animals and food intake
At the start of the study, mean body weight of the animals
was 243 g. Average food intake before infection was 19 g/
d in the control and cystine group, and 17 g/d in the BSO
group (p < 0.05). Post infection, food intake was 16 g/d in
all groups. Mean body weight gain prior to infection was
5 g/d. After infection, average body weight gain was 3 g/d
in all groups.
BSO decreases the glutathione content in liver and ileum 
mucosa
BSO decreased hepatic glutathione by 48% in the infected
animals in comparison with the control group (Figure 1A;
p < 0.05). Cystine supplementation did not significantly
affect liver glutathione of non-infected rats. Post-infection
levels were 21% higher in cystine-fed animals, although
this increase did not reach statistical significance. BSO
decreased ileal mucosal glutathione by ≥ 98% in non-
infected and infected rats (Figure 1B; p < 0.05). Dietary
cystine did not increase ileal glutathione in non-infected
or infected rats.
BSO is a competitive inhibitor of gamma-GCS and could
possibly cause an accumulation of cysteine in the ileum
mucosa. However, mucosal cysteine levels were decreased
in BSO treated animals (data not shown).
Diarrhoea, faecal excretion and translocation of 
Salmonella
Glutathione depletion increased relative faecal wet weight
in non-infected animals whereas cystine had no effectBMC Physiology 2009, 9:6 http://www.biomedcentral.com/1472-6793/9/6
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(Figure 2A). After infection, there was no difference in
diarrhoea between the control and BSO group or between
the control and cystine group.
Faecal Salmonella excretion was similar in all diet groups
on the first and third day after Salmonella infection (107
and 106  colony-forming units (CFU)/g faeces, respec-
tively), indicating identical intestinal colonisation levels
in all groups. Furthermore, depletion of mucosal glutath-
ione did not affect Salmonella translocation to liver and
spleen (Figure 2B). In contrast, cystine decreased the
number of Salmonella in both tissues (Figure 2B), pointing
to a protective effect of cystine on Salmonella translocation
to extra-intestinal organs.
Total glutathione in liver and ileum mucosa Figure 1
Total glutathione in liver and ileum mucosa. Total glutathione in liver (A) and ileum mucosa (B) of rats fed the control 
diet (white bars) or the same diet supplemented with buthionine sulfoximine (BSO; grey bars) or cystine (black bars). Rats 
were orally infected with 1.109colony-forming units S. enteritidis (n = 8 per diet) or received saline only (non-infected animals; n 
= 6 per diet). Results are expressed as means ± SE. An asterisk indicates a significant difference from the control diet group 
(either non-infected or infected rats; p < 0.05).
Relative faecal wet weight and Salmonella translocation Figure 2
Relative faecal wet weight and Salmonella translocation. Relative faecal wet weight (A) before (n = 6 per diet group) 
and after oral S. enteritidis infection (n = 8 per diet group) of rats fed the control diet (white bars) or the same diet supple-
mented with BSO (grey bars) or cystine (black bars). Translocation of S. enteritidis as determined by viable pathogen counts (B) 
in liver and spleen. Results are expressed as means ± SE. CFU means colony-forming units. An asterisk indicates a significant 
difference from the control diet group (either non-infected or infected rats; p < 0.05).BMC Physiology 2009, 9:6 http://www.biomedcentral.com/1472-6793/9/6
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Mucosal antioxidant capacity
In response to a serious decrease of glutathione, the body
could compensate by increasing other (non-thiol) anti-
oxidants. Therefore we investigated the total mucosal anti-
oxidant capacity of non-thiols by determining the ferric
reducing ability of mucosal tissue. Neither BSO nor cys-
tine changed the mucosal non-thiol antioxidant capacity
before infection. The same results were found in infected
rats (Figure 3).
Mucosal inflammation and oxidative damage
Despite identical colonisation levels, the glutathione-
depleted rats, presumably with lower antioxidant capac-
ity, had increased ileal mucosal IL-1β levels (Figure 4A).
This coincided with a more intensive inflammatory
response in this group as measured by ileal MPO (Figure
4B). However, this did not increase oxidative-stress
related mucosal damage like protein carbonyls (Figure
4C) and mucosal lipid peroxidation, measured by thio-
barbituric acid reactive substances (TBARS; results not
shown). Despite protective effects of cystine on Salmonella
translocation and maintenance of glutathione levels,
intestinal inflammation and oxidative damage markers
were not decreased in this group (Figure 4).
Intestinal permeability
In general, the Salmonella infection increased paracellular
intestinal permeability with time (Figure 5). Despite
increased mucosal inflammation in BSO treated animals,
intestinal permeability was not aggravated. In contrast,
the results suggest a decrease in comparison with the con-
trol group (Figure 5). Moreover, cystine partially restored
infection-induced intestinal permeability to basal (pre-
infection) levels, suggesting a beneficial effect of cystine
on gut barrier function. Neither BSO nor cystine supple-
mentation affected intestinal permeability in non-
infected rats (data not shown).
Nitric oxide response is not affected by the cystine diet
Since diet composition can affect the inducible nitric
oxide (NO) production capacity in response to microbial
stimuli, the effect of dietary cystine was investigated in an
LPS experiment. Urinary NOx (sum of nitrate and nitrite)
excretion in response to intraperitoneally administered
lipopolysaccharide (LPS) was identical in the control and
cystine group (data not shown), demonstrating equal host
capacity to produce NO.
Discussion
The present study shows that depletion of glutathione
during Salmonella infection results in increased mucosal
inflammation. However, as Salmonella translocation was
not affected by BSO treatment, glutathione depletion
obviously does not affect mucosal barrier function. Also,
urinary excretion of the paracellular permeability marker
chromium ethylenediamine-tetraacetic acid (CrEDTA)
was not increased in comparison with infected rats fed the
control diet. On the other hand, cystine supplementation
resulted in improved barrier function and decreased Sal-
monella counts in extra-intestinal organs. However, the
subsequent ileal inflammation was not reduced. Since
cystine did not significantly increase glutathione and
inflammation was not reduced the results suggest that the
protective mechanism of cystine supplementation is not
related to mucosal glutathione levels. Most likely other
host defences than glutathione are strengthened by cys-
tine.
In line with other studies, oral administration of BSO, a
selective inhibitor of glutathione synthesis, decreased
hepatic glutathione levels[26,27]. Nearly complete deple-
tion was observed in ileal mucosa of both infected and
non-infected animals. A decrease of intestinal glutathione
is shown during necrotising enterocolitis in rats[15] and
in mouse ileal loops exposed to Salmonella typhimu-
rium[16]. This decrease is suggested to contribute to
pathogenesis of disease and subsequent failure of barrier
integrity[15,16]. Our results now show that depletion of
glutathione does not necessarily lead to impaired intesti-
nal barrier function. A study with mice indicated that glu-
tathione-depletion by BSO caused mucosal damage in the
jejunum and colon[28]. However, a much higher dose of
BSO was applied, increasing the risk of pharmacological
side-effects of BSO in that study. The lower dose used in
our study, nearly depleted intestinal mucosal glutathione
but hardly affected body weight gain and did not result in
Ferric reducing ability of non-thiols in the ileum mucosa Figure 3
Ferric reducing ability of non-thiols in the ileum 
mucosa. Ferric reducing ability of non-thiols in the ileum 
mucosa of non-infected rats (n = 6 per diet) and S. enteritidis 
infected rats (n = 8 per diet) fed the control diet (white bars) 
or the same diet supplemented with BSO (grey bars) or cys-
tine (black bars). All results are expressed as means ± SE. No 
significant differences were detected between the control 
diet group and the BSO or cystine-supplemented group.BMC Physiology 2009, 9:6 http://www.biomedcentral.com/1472-6793/9/6
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histological mucosal damage in haematoxylin- and eosin-
stained ileum sections (data not shown).
The oral Salmonella infection in our experiment had no or
little effect on liver and ileal mucosal glutathione at 4 days
post infection, indicating that the organ-specific capacity
to synthesise glutathione was adequate or that infection-
induced oxidative stress was absent in normally fed rats
(diet adequate in antioxidants). In previous studies we
(unpublished results) and others[15] detected a tempo-
rarily decrease of intestinal glutathione after an intestinal
insult. So, intestinal glutathione levels may differ depend-
ing on the time point studied, which may result in seem-
ingly contrasting results. For example, in our in-vivo
study, glutathione was determined at 4 days after infec-
tion and levels were not (or no longer) decreased. How-
ever, a reduction in glutathione was reported in an ileal
loop study at 18 hrs after Salmonella introduction [16].
Furthermore, studies limited to specific cell types, for
example enterocytes isolated from infected animals[16],
may show different results from in vivo studies investigat-
ing complete mucosa. Specifically, during infection T lym-
phocytes and macrophages migrate into the intestinal
mucosa and these cells are also able to synthesise glutath-
ione and thus contribute to mucosal glutathione [23,29].
In our study, oxidative damage in the form of intestinal
protein carbonyls or TBARS was not detected when intes-
tinal glutathione was depleted (BSO treated rats). Oxida-
tive damage induced by glutathione depletion has been
shown in plasma lipids [30] and liver (DNA adducts)[26],
however those studies did not investigate the intestine.
Supplementation of cystine maintained intestinal glutath-
ione levels similar to the control diet group. Surprisingly,
inflammation was not reduced despite a decrease in intes-
tinal permeability and significant inhibition of Salmonella
translocation. Improvement of gut barrier function has
also been described for intraperitoneally administered N-
acetylcysteine in partially hepatectomised rats[31]. The
reduced viable Salmonella counts in liver and spleen of the
cystine-fed rats in our study may have resulted from
Inflammation and oxidative damage in the ileummucosa Figure 4
Inflammation and oxidative damage in the ileummucosa. BSO increased inflammation in the ileum mucosa of S. enteri-
tidis infected rats. S. enteritidis infected (n = 8 per diet) and non-infected (n = 6 per diet) rats were fed the control diet (white 
bars) or the same diet supplemented with BSO (grey bars) or cystine (black bars). Mucosal levels of the pro-inflammatory 
cytokine interleukin-1β (IL-1β) and myeloperoxidase (MPO) are shown in panels A and B, respectively. Recovery experiments 
with purified IL-1β and MPO, added to the mucosal samples, were included in each assay and confirmed the absence of inhibit-
ing factors in the ileal samples. Oxidative damage to ileal proteins was determined by measurement of protein carbonyls (C). 
All results are expressed as means ± SE. An asterisk indicates a significant difference from the control diet group (either non-
infected or infected rats; p < 0.05).
Infection-induced urinary excretion of dietary CrEDTA Figure 5
Infection-induced urinary excretion of dietary 
CrEDTA. Infection-induced urinary excretion of dietary 
CrEDTA after oral S. enteritidis infection (n = 8 per diet) in 
rats fed the control diet or the same diet supplemented with 
BSO or cystine. Results, expressed as means ± SE, were cor-
rected for baseline (pre infection) permeability. Baseline 
CrEDTA output was identical in all groups. The asterisk indi-
cates a significant difference from the control group (p < 
0.05).BMC Physiology 2009, 9:6 http://www.biomedcentral.com/1472-6793/9/6
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decreased Salmonella translocation from the gut or from
enhanced killing of translocated pathogens by the innate
immune system, e.g.  by increased production of nitric
oxide (NO)[32,33]. N-acetylcysteine can enhance this NO
defence[34], but the effect of cystine was unknown. Our
LPS experiment revealed that rats fed the control and cys-
tine diet responded identically to an intraperitoneal LPS
challenge, excluding differences in the NO-based capacity
of the host to kill bacterial invaders. Therefore, the lower
Salmonella counts in liver and spleen observed here prob-
ably reflect reduced translocation of this pathogen from
the gut lumen.
Surprisingly, infection-induced intestinal permeability of
BSO-treated animals seemed lower than that of the con-
trol group (Figure 5) but the effect was not significant.
One could hypothesize that competitive inhibition of
gamma-GCS may cause accumulation of cysteine in the
mucosa, resulting in protective effects as seen on the cys-
tine diet. However, mucosal cysteine levels were decreased
in BSO treated animals. Furthermore, in contrast to the
cystine fed rats, no protective effect against Salmonella
translocation was observed in these animals.
The mucosal barrier enhancing effect of cystine requires
further investigation. Results need to be reproduced and
the mechanism behind the protective effect should be
explored. Cysteine can play a role in various host
defences. For instance, trefoil peptides, which stabilise
mucosal glycoproteins and protect the mucosa from vari-
ous insults, e g bacterial toxins[35], contain several
cysteine-rich domains[35,36]. In addition, defensins,
which are antimicrobial peptides secreted by human and
rodent ileal Paneth cells, contain 6 conserved
cysteines[37] and are important for intestinal resistance to
Salmonella infection[38]. Although, cysteine is not an
essential amino acid and can be synthesised from methio-
nine, it might be conditionally essential like suggested for
glutamine[39,40].
Conclusion
In conclusion, intestinal depletion of glutathione is not as
detrimental for maintenance of the gut barrier as often
presumed. Neither paracellular intestinal permeability
nor Salmonella translocation were promoted at very low
mucosal glutathione levels, despite increased infection-
induced ileal inflammation. On the other hand, dietary
cystine did not reduce infection-associated inflammation
but decreased intestinal permeability and Salmonella
translocation to extra-intestinal organs by a mechanism
unlikely related to glutathione. Follow-up studies are
needed to elucidate the molecular mechanism(s) underly-
ing the protective effect of cystine supplementation on gut
barrier function and to address human relevance.
Methods
Diets, infection and dissection of the rats
The animal experiments were approved by the animal
welfare committee of Wageningen University (Wagenin-
gen, the Netherlands). Specific-pathogen-free male Wistar
rats (WU, Harlan, Horst, the Netherlands), 8 weeks old at
the start of the dietary intervention, were housed individ-
ually in metabolic cages. Rooms were temperature (20–
21°C) and humidity-controlled (50–60%) with a 12:12-
hour light/dark cycle. Rats were fed purified diets contain-
ing per kg: 200 g acid casein, 326 g cornstarch, 174 g glu-
cose, 160 g palm oil, 40 g corn oil, 50 g cellulose and
vitamin and mineral mix (without calcium) according to
AIN-93[41]. To mimic the composition of a Western
human diet, the prepared diets were relatively low in cal-
cium (30 mmol/kg) and high in fat content (200 g/kg) in
comparison with recommendations for rodent diets by
AIN-93. This control diet was supplemented with DL-
buthionine(S,  R)-sulfoximine (BSO) or L-cystine (both
purchased from Sigma-Aldrich, St. Louis, Missouri, USA),
at the expense of glucose, to a final concentration of 7.5
mmol/kg and 12.3 mmol/kg, respectively. Nitrogen cor-
rection of the diets was considered unnecessary, since the
contribution of cystine was marginal (0.035%). In addi-
tion, the inert intestinal permeability marker CrEDTA was
added to the diets[42,43]. Preparation and purity control
of CrEDTA was performed as described [44-46]. The
CrEDTA solution was lyophilised in a manifold freeze
dryer (FD5515; Ilshin Laboratory Co Ltd, Seoul, South
Korea) and the dry material obtained was added to the
diets to a final concentration of 2 g/kg.
Food and demineralised drinking water were supplied ad
libitum. Body weight and food intake were recorded twice
a week before infection and daily after infection. One
group was fed the control diet and another group was fed
the cystine-supplemented diet (n = 14 per diet). The third
group (n = 14) was fed the control diet for one week, fol-
lowed by the BSO diet for the remaining study period.
Animals were acclimatised to housing and dietary condi-
tions for 21 days, after which 8 animals per diet group
were orally infected with 1 ml of saline containing 1.109
CFU of Salmonella enteritidis(clinical isolate, phage type
4; strain B1214 NIZO food research, Ede, the Nether-
lands) as described elsewhere[47]. The other 6 animals
per diet group were not infected and received 1 ml saline
orally.
In previous Salmonella infection studies in rats we have
found that levels of ileal mucosal glutathione change with
time (unpublished). After an initial decrease, total glu-
tathione levels start to recover at day 4 post infection. Fur-
thermore, for monitoring functional infection outcomesBMC Physiology 2009, 9:6 http://www.biomedcentral.com/1472-6793/9/6
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like Salmonella colonisation, translocation and infection-
induced permeability changes, follow-up of infected rats
for at least 3 to 4 days is needed. Therefore section was
performed at day 4 after infection (or sham treatment).
Rats were randomly selected and killed by carbon dioxide
inhalation. During the dissection, the distal 12 cm of the
ileum was excised and cut open longitudinally. After
flushing rapidly with saline, the mucosa was scraped off
with a spatula and immediately frozen in liquid nitrogen
for protein analyses. Furthermore, the spleen and liver
were aseptically excised and after homogenisation in ster-
ile saline directly used for Salmonella quantification, as
described elsewhere[48]. Another part of the liver was
immediately frozen in liquid nitrogen for further prepara-
tion and analyses as described below.
Fresh faecal samples were collected to quantify Salmonella
colonisation prior to infection and 1 and 3 days post
infection, as described elsewhere[49]. In addition, 24h
faeces (pooled per animal in both the pre-infection and
post-infection period) and urines were collected from 2
days before infection until 4 days after oral Salmonella
administration. All faeces and urine samples were stored
at -20°C until further analysis. Oxytetracycline (Sigma-
Aldrich) was added to the urine collection vessels of the
metabolic cages to prevent bacterial deterioration.
Salmonellacolonisation and diarrhoea
Faecal Salmonella was determined in fresh faecal samples
collected with time as described elsewhere[49]. Total 24 h
faeces were lyophilized in a manifold freeze dryer
(FD5515; Ilshin Laboratory Co Ltd). Faecal water was pre-
pared as described previously and osmolarity was meas-
ured (Osmomat 030-D, Gonotec, Berlin, Germany) to
calculate the percentage wet weight[50]. Direct determi-
nation of faecal wet weight by lyophilisation was consid-
ered inappropriate because this underestimates relative
faecal wet weight due to evaporation of water from the
faecal pellets in the collection vessels of the metabolic
cages.
Intestinal permeability analysis
CrEDTA excreted in 24 h urine samples was determined
by inductively coupled plasma atomic emission spectros-
copy (ICP-AES; Varian, Mulgrave, Australia) as described
elsewhere[45]. Urinary CrEDTA output was expressed as
percentage of dietary intake. Infection-induced urinary
excretion of CrEDTA was corrected for baseline (pre-infec-
tion) levels. Urine was tested negative for faecal contami-
nation by checking the absorption spectrum 400–600 nm
for bile pigments. These pigments are present in faeces but
absent in urine.
Tissue sample preparation
Frozen liver tissue and ileal mucosa were pulverised under
liquid nitrogen. Frozen pulverised tissue was suspended
in a 0.2 M sucrose buffer of pH 7.4 containing 20 mM
trishydroxymethylaminomethane (Tris), 1 mM dithioth-
reitol (DTT; Sigma Aldrich) and Complete Protease Inhib-
itor Cocktail (Roche Diagnostics, Basel, Switzerland) and
sonicated on ice for 20–30 s at level 2–3 (Sonicator
XL2020, Heat Systems, Farmingdale, New York, USA).
The protein concentration of the samples was determined
using biocinchoninic acid (BC) Assay (Omnilabo,
Veenendaal, the Netherlands).
Total glutathione and cysteine analyses
Total glutathione in liver and ileum was measured using a
slightly modified assay described by Mansoor et al[51].
This method determines the total of reduced, oxidized,
and protein-bound forms of glutathione by HPLC with-
out discrimination of the individual forms. As a result,
total glutathione levels are presented and indicated in the
text by 'glutathione'. Compared to the original method,
twice the sample volumes and reagents were used. Briefly,
samples of 25 μl were injected into a 150 × 4.6 mm, 3 μm
PLRP-S column, equipped with a PLRP-S guard column
(Polymer Laboratories, Amherst, Massachuessetts, USA).
Flow rate was 1 ml/min at 30°C with elution solvent A
(0.1% trifluoric acid (TFA), 5% acetonitrile) and solvent B
(0.1% TFA, 80% acetonitrile), both diluted with distilled
water. Chemicals were purchased from Sigma-Aldrich.
The elution profile was as follows: 0–20 min, 0% B; 20–
25 min, 16% B; 25–30 min 50% B, with retention time of
bimane derivatives of glutathione of 23 min. A Spectra
Systems FL2000 fluorometer (Spectra Physics, Mountain
View, California, USA) was used for detection, with exci-
tation and emission at 394 and 480 nm, respectively. Plot-
ting and integration of peaks were performed by
Chromeleon software 6.6 (Dionex, Sunnyvale, California,
USA). Total glutathione results are expressed as μmol/g
tissue protein.
In the samples described above cysteine, identified as a
separated peak in chromatograms, was determined iden-
tically and simultaneously with the glutathione analysis.
Mucosal antioxidant capacity
Mucosal antioxidant capacity of non-thiols, thus exclud-
ing glutathione, was determined using the ferric reducing
ability method as described for plasma[52]. Briefly, to 33
μl ileum sample 1 ml of ferric reducing ability reagent was
added[52]. Antioxidant capacity is expressed as nmol Fe2+
formed per mg protein.
Mucosal inflammation and oxidative damage
A mouse MPO ELISA test kit (Hycult biotechnology,
Uden, the Netherlands), which is cross-reactive with rat
MPO, was used to determine the concentration of MPO in
mucosal scrapings. IL-1β levels were determined using an
ELISA kit (Biosource, Nivilles, Belgium).BMC Physiology 2009, 9:6 http://www.biomedcentral.com/1472-6793/9/6
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To evaluate lipid peroxidation, TBARS in the mucosal
samples were determined according to Ohkawa[53],
using 100 μl of undiluted sample[50]. Control experi-
ments with reference samples, known to have TBARS,
were analysed positive. In addition, spiking of ileal
mucosal samples of the present study with the reference
material showed good recovery of TBARS.
Ileal protein carbonyls, as marker of protein oxidation,
were measured by an ELISA according to the method of
Buss  et al.[54]. Briefly, standards and samples were
diluted in phosphate-buffered saline to a protein concen-
tration of 4 mg/ml. Carbonyls were derivatised with 2,4-
dinitrophenyl hydrazine (Sigma-Aldrich) and coated on
an ELISA plate (Nunc-Immuno plate maxisorp, Nunc,
Roskilde, Denmark). After probing with biotinylated anti-
2,4-dinitrophenyl hydrazine antibody (Molecular Probes
Inc, Eugene, Oregon, USA), streptavidin-biotinylated
horseradish peroxidase (Amersham Biosciences, Piscata-
way, New Jersey, USA) was incubated in the wells. Stain-
ing was performed with o-phenylenediamine (Sigma-
Aldrich). Absorbance was read at 490 nm in a ThermoMax
microplate reader (Molecular Devices Corp, Sunnyvale,
California, USA).
S. enteritidis lipopolysaccharide experiment
To study the effect of dietary cystine on the capacity of rats
to generate NO in response to systemic bacterial stimuli,
rats (n = 8 per group) fed the control or cystine diet (die-
tary acclimatisation of 14 days) were intraperitoneally
injected with 0.5 mg/kg LPS, as described elsewhere [48].
The LPS used was derived from S. enterica Serovar enteri-
tidis, which is identical to the strain used in the oral infec-
tion study. Animals were monitored until 3 days after
challenge and 24 h urines were collected. The NO
response was quantified by measuring urinary NOx (sum
of nitrate and nitrite) excretion by using a colorimetric
enzymatic kit (Roche Diagnostics), as described else-
where[55].
Statistical analysis
All data are expressed as means ± SE. Data were tested for
normality by the Kolmogorov-Smirnov test. If normally
distributed, differences between the control and dietary
intervention groups (cystine or BSO) were tested for sig-
nificance using one-way ANOVA, followed by Bonfer-
roni's multiple-comparison test. Our aim was to
investigate dietary effects in the non-infection and the
infection period separately. Therefore, differences
between non-infected and infected groups were not
tested. When data of groups showed unequal variances,
the Kruskal-Wallis test was used, followed by Dunn's post
test for multiple comparisons. Statistical significance was
set at p < 0.05.
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